IDEXX Laboratories, Inc. (IDXX)
IDEXX Laboratories, Inc. (IDXX) is a healthcare company (diagnostics & research) based in the United States. The share price is $695.48, down 0.74% on the day, which values the company at $54.79B. Price as of 17 Nov 2026, 17:16 UTC, from Yahoo Finance.
Key facts
- Share price
- $695.48−0.74% today
- Market value
- $54.79B
- P/E ratio
- 46.9×last 12 months
- Forward P/E
- 41.2×
- Funk Score
- 67/100
- Against its own history
- Above its usual priceusual price $552.14
- 200-week average
- $526.7732% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
IDEXX Laboratories, Inc. in more detail
IDXX trades at 46.9× its last twelve months' earnings, 41.2× next year's expected earnings, 11.8× sales. Measured against its own history, the price is 26% above what its usual multiples would imply ($552.14) — above its usual price. It sits 32% above its 200-week average of $526.77.
Over the last five fiscal years IDEXX Laboratories, Inc. has compounded revenue 9.7% a year, earnings per share 14.3% a year, free cash flow 14.0% a year. Its Funk Score is 67 out of 100 (financial strength 8.0, profitability 9.4, growth 6.9, value 2.4, each out of 10).
In its favour: Altman Z in the safe zone; Strong Piotroski score.
10 of the superinvestors tracked here hold IDXX, including Terry Smith (2.9% of the portfolio), Polen Capital team (2.2% of the portfolio), Jensen team (1.8% of the portfolio).
Superinvestors holding IDXX
10 of the investors tracked here report a position in their latest 13F filing.
- Terry Smith Fundsmith2.89% of portfolio · $373.3M · trimmed · Q3 2026
- Polen Capital team Polen Capital Management2.23% of portfolio · $205M · trimmed · Q3 2026
- Jensen team Jensen Investment Management1.81% of portfolio · $57.8M · added · Q3 2026
- Ron Baron Baron Capital (BAMCO)1.56% of portfolio · $930.8M · trimmed · Q3 2026
- Wallace Weitz Weitz Investment Management1.28% of portfolio · $18.7M · added · Q3 2026
- Brandon Haley Holocene Advisors0.21% of portfolio · $92.4M · added · Q2 2026
- Steve Cohen Point72 Asset Management0.21% of portfolio · $138.4M · added · Q2 2026
- Baillie Gifford team Baillie Gifford & Co0.14% of portfolio · $151.5M · trimmed · Q3 2026
- Mairs & Power team Mairs & Power0.01% of portfolio · $1.1M · added · Q3 2026
- Bill Nygren Harris Associates (Oakmark)0.00% of portfolio · $239.5K · trimmed · Q2 2026
Health Care companies of similar size
- Takeda PharmaceuticalTAK
- CencoraCOR
- Boston ScientificBSX
- Cardinal HealthCAH
- argenxARGX
- Edwards LifesciencesEW
- Becton, DickinsonBDX
- MedlineMDLN
- HumanaHUM
- Agilent TechnologiesA
- Teva Pharmaceutical IndustriesTEVA
- BeOne MedicinesONC
Side by side:IDXX vs MDLN (IDEXX Laboratories, Inc. vs Medline)IDXX vs BDX (IDEXX Laboratories, Inc. vs Becton, Dickinson)IDXX vs EW (IDEXX Laboratories, Inc. vs Edwards Lifesciences)IDXX vs ARGX (IDEXX Laboratories, Inc. vs argenx)IDXX vs HUM (IDEXX Laboratories, Inc. vs Humana)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
IDEXX Laboratories, Inc. (IDXX): questions and answers
What is IDXX's P/E ratio?
IDEXX Laboratories, Inc. trades at 46.9× its last twelve months' earnings and 41.2× next year's expected earnings. At its fiscal year-ends over the past 18 years the P/E ranged from 19.3× to 76.6×, with a median of 42.5×.
What is IDXX's PEG ratio?
IDEXX Laboratories, Inc.'s PEG ratio is 3.27 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is IDEXX Laboratories, Inc.'s market cap?
IDEXX Laboratories, Inc. is valued at $54.79B at a share price of $695.48.
Is IDXX overvalued or undervalued?
Against its own history, IDXX is above its usual price: the price is 26% above the $552.14 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is IDXX above its 200-week moving average?
Yes. IDXX is 32.0% above its 200-week average of $526.77. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is IDEXX Laboratories, Inc. growing?
Over the last five fiscal years IDEXX Laboratories, Inc.'s revenue grew 9.7% a year and its earnings per share 14.3% a year; over ten years revenue grew 10.4% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “IDEXX Laboratories, Inc. (IDXX) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/IDXX
Underlying data: Yahoo Finance; company filings with the SEC.